Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study
Phase of Trial: Phase IV
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Acronyms COBRRA
- 13 Apr 2018 Status changed from active, no longer recruiting to completed.
- 05 Jan 2018 Planned End Date changed from 1 Sep 2017 to 1 Feb 2018.
- 12 Dec 2017 Primary endpoint (Proportion of eligible patients who consent to participate in the trial) has been met as per the results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology